Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E Sax; David Wohl; Michael T Yin; Frank Post; Edwin DeJesus; Michael Saag; Anton Pozniak; Melanie Thompson; Daniel Podzamczer; Jean Michel Molina; Shinichi Oka; Ellen Koenig; Benoit Trottier; Jaime Andrade-Villanueva; Gordon Crofoot; Joseph M Custodio; Andrew Plummer; Lijie Zhong; Huyen Cao; Hal Martin; Christian Callebaut; Andrew K Cheng; Marshall W Fordyce; Scott McCallister

doi:10.1016/s0140-6736(15)60616-x

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

The Lancet ◽

10.1016/s0140-6736(15)60616-x ◽

2015 ◽

Vol 385 (9987) ◽

pp. 2606-2615 ◽

Cited By ~ 334

Author(s):

Paul E Sax ◽

David Wohl ◽

Michael T Yin ◽

Frank Post ◽

Edwin DeJesus ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Faculty Opinions recommendation of Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725442708.793509558 ◽

2015 ◽

Author(s):

Anthony Harries

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Faculty Opinions recommendation of Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954439.793460355 ◽

2012 ◽

Author(s):

Kiat Ruxrungtham ◽

Wirach Maek-a-nantawat

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Hiv 1

Download Full-text

Longer-Term Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide Versus Emtricitabine and Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Week 96 Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3772801 ◽

2021 ◽

Author(s):

Onyema Ogbuagu ◽

Peter J. Ruane ◽

Daniel Podzamczer ◽

Laura C. Salazar ◽

Keith Henry ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Tenofovir Alafenamide ◽

Exposure Prophylaxis ◽

Hiv 1

Download Full-text

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(17)32340-1 ◽

2017 ◽

Vol 390 (10107) ◽

pp. 2073-2082 ◽

Cited By ~ 97

Author(s):

Paul E Sax ◽

Anton Pozniak ◽

M Luisa Montes ◽

Ellen Koenig ◽

Edwin DeJesus ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(19)30077-3 ◽

2019 ◽

Vol 6 (6) ◽

pp. e355-e363 ◽

Cited By ~ 27

Author(s):

David A Wohl ◽

Yazdan Yazdanpanah ◽

Axel Baumgarten ◽

Amanda Clarke ◽

Melanie A Thompson ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(12)60918-0 ◽

2012 ◽

Vol 379 (9835) ◽

pp. 2429-2438 ◽

Cited By ~ 245

Author(s):

Edwin DeJesus ◽

Jürgen K Rockstroh ◽

Keith Henry ◽

Jean-Michel Molina ◽

Joseph Gathe ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Hiv 1

Download Full-text

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet HIV ◽

10.1016/s2352-3018(21)00071-0 ◽

2021 ◽

Vol 8 (7) ◽

pp. e397-e407

Author(s):

Onyema Ogbuagu ◽

Peter J Ruane ◽

Daniel Podzamczer ◽

Laura C Salazar ◽

Keith Henry ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Tenofovir Alafenamide ◽

Exposure Prophylaxis ◽

Hiv 1

Download Full-text

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(17)32299-7 ◽

2017 ◽

Vol 390 (10107) ◽

pp. 2063-2072 ◽

Cited By ~ 107

Author(s):

Joel Gallant ◽

Adriano Lazzarin ◽

Anthony Mills ◽

Chloe Orkin ◽

Daniel Podzamczer ◽

...

Keyword(s):

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Tenofovir Alafenamide ◽

Randomised Controlled ◽

Hiv 1

Download Full-text

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

The Lancet HIV ◽

10.1016/s2352-3018(16)00024-2 ◽

2016 ◽

Vol 3 (4) ◽

pp. e158-e165 ◽

Cited By ~ 100

Author(s):

Joel E Gallant ◽

Eric S Daar ◽

François Raffi ◽

Cynthia Brinson ◽

Peter Ruane ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Fixed Dose ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(20)30241-1 ◽

2020 ◽

Vol 7 (10) ◽

pp. e666-e676 ◽

Cited By ~ 3

Author(s):

Willem D F Venter ◽

Simiso Sokhela ◽

Bryony Simmons ◽

Michelle Moorhouse ◽

Lee Fairlie ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text